Table 1. Patient characteristics and tumor uptake of FDG and FDOPA.
| Characteristics | No. | FDG Uptake* | P† | FDOPA Uptake* | P† | G:D Ratio* | P† |
|---|---|---|---|---|---|---|---|
| All patients | 42 | 4.07 (2.76–6.36) | – | 3.54 (2.79–5.03) | – | 1.40 (0.75–1.89) | – |
| Gender | 0.35 | 0.46 | 0.73 | ||||
| Female | 14 | 3.25 (2.49–5.64) | 3.53 (2.32–4.72) | 1.29 (0.75–1.75) | |||
| Male | 28 | 4.53 (2.84–6.99) | 3.54 (2.94–6.09) | 1.40 (0.66–2.25) | |||
| Age group | 0.0095 | 0.01 | 0.0018 | ||||
| < 18 months | 18 | 2.83 (2.24–5.09) | 5.06 (2.96–6.65) | 0.79 (0.35–1.59) | |||
| ≥ 18 months | 24 | 5.09 (3.56–7.60) | 3.28 (2.59–3.70) | 1.64 (1.09–2.61) | |||
| Stage | 0.0069 | 0.0013 | 0.0005 | ||||
| 1/2/3/4S | 6/1/9/1 | 2.77 (1.94–4.29) | 5.00 (3.46–6.67) | 0.61 (0.32–1.26) | |||
| 4 | 25 | 5.16 (3.40–7.31) | 3.09 (2.43–3.61) | 1.67 (1.04–2.56) | |||
| MYCN | 0.0067 | 0.11 | 0.0023 | ||||
| Non-amplified | 33 | 3.79 (2.64–5.11) | 3.59 (2.95–5.30) | 0.99 (0.57–1.63) | |||
| Amplified | 9 | 6.85 (5.64–8.17) | 3.24 (2.04–3.66) | 1.86 (1.69–2.90) | |||
| Genomic type | 0.0003 | 0.0074 | 0.0001 | ||||
| Numerical | 11 | 2.68 (2.1–3.0) | 5.49 (4.12–7.34) | 0.43 (0.27–0.78) | |||
| Segmental | 7 | 5.01 (3.48–5.76) | 3.58 (3.33–3.70) | 1.35 (0.99–1.61) | |||
| MYCN-amplified | 9 | 6.85 (5.64–8.17) | 3.24 (2.04–3.66) | 1.86 (1.69–2.90) | |||
| Flat/IGF2‡ | 3/1 | 6.38 (1.73–12.45) | 3.95 (2.14–6.19) | 1.29 (0.51–3.63) | |||
| Histology | 0.70 | 0.95 | 0.67 | ||||
| UNB/PDNB | 9/26 | 4.10 (3.03–6.19) | 3.58 (2.85–5.00) | 1.44 (0.78–1.86) | |||
| DNB/GNBi | 3/2 | 2.72 (1.75–11.38) | 3.48 (2.39–5.76) | 0.92 (0.58–2.84) | |||
| NB, unspecified‡ | 2 | – | – | – | |||
| Risk group | 0.0037 | 0.0057 | 0.0008 | ||||
| Low | 7 | 2.30 (1.62–2.77) | 5.49 (4.12–6.72) | 0.43 (0.27–0.98) | |||
| Intermediate | 5 | 3.03 (2.04–7.72) | 6.62 (4.06–9.10) | 0.61 (0.26–1.33) | |||
| High | 30 | 5.11 (3.44–7.17) | 3.28 (2.55–3.69) | 1.64 (1.06–2.43) | |||
| Site | 0.97 | 0.69 | 0.78 | ||||
| Adrenal | 29 | 4.05 (2.70–6.94) | 3.48 (2.43–5.24) | 1.49 (0.64–2.34) | |||
| RP/Med | 11/2 | 4.10 (3.11–5.47) | 3.59 (2.91–4.61) | 1.35 (0.89–1.74) | |||
| IDRF | 0.03 | 0.24 | 0.03 | ||||
| 0 | 15 | 2.77 (1.80–5.60) | 4.12 (2.45–6.47) | 0.98 (0.22–0.97) | |||
| ≥ 1 | 27 | 4.59 (3.32–7.03) | 3.41 (2.85–4.09) | 1.61 (0.80–2.33) |
Presented as median (interquartile range).
By two-tailed Kruskal-Wallis test; P values in bold font indicate significance.
These categories were not included in statistical analyses.
Abbreviations: CR = complete response after induction chemotherapy; DNB = differentiating neuroblastoma; GNBi, ganglioneuroblastoma, intermixed; G:D = the ratio between the SUVmax of FDG and FDOPA; GTR = gross total resection; IDRF, image-defined risk factor; IGF2 = Beckwith-Wiedemann syndrome with IGF2 microdeletion; IQR = interquartile range; Med = mediastinal; NA = second operation was not attempted due to ongoing chemotherapy or disease progression; NB = neuroblastoma; PDNB = poorly-differentiated neuroblastoma; RP = retroperitoneal; UNB = undifferentiated neuroblastoma; GNBi = ganglioneuroblastoma, intermixed.